Prodigy diligently monitors new-to-market drugs approved by the U.S. Food and Drug Administration (FDA). Our comprehensive pipeline report includes all novel drugs, regardless of whether they are currently indicated for conditions covered under workers’ compensation. This report equips claims professionals with essential background information that can prove invaluable if these drugs are prescribed, either for their indicated conditions or for off-label use. By staying informed about these emerging therapies, claims professionals can make more informed decisions and better manage patient care.
2Q 2025 FDA New Drug Approvals
Previous
Previous
2Q 2025 Top 10 Drugs and Therapy Classes
Next
Next

